The RCVS Disciplinary Committee has suspended a Kent veterinary surgeon from the Register for eight months after he was found guilty of dishonest certification.
At the outset of the hearing held on 14/15 December, Takeshi Okano, of Lakeview Veterinary Centre in Deal, Kent, admitted charges that, whilst acting as Official Veterinarian, he had signed a number of certificates when he knew that did not have all the information needed to do so.
On 23 June 2009, Mr Okano had been asked to act as Official Veterinarian to examine four horses and sign the certificates necessary for their export to the USA. The certificates required Mr Okano to certify he had received a written declaration from the owners that the animals had been in the UK for 60 days previously. Mr Okano also signed certificates indicating that the horses had only been in France, Ireland, or the UK for the same 60-day period. Despite having received no such declarations, and having no information whatsoever of where the horses had been, Mr Okano signed the certificates. At the hearing, no explanation for Mr Okano's actions was offered.
Mrs Beverley Cottrell, Chairman of the Disciplinary Committee said: "The validity of any certificate is an integral part of the system relating to the export or import of animals. At Section G of the RCVS Guide to Professional Conduct, emphasis is given to the importance of certification, the importance of the signature and the guidance issued by DEFRA. These provisions are well known to the profession."
The Committee was satisfied that Mr Okano's actions in signing the certificates without the owners' declarations amounted to a serious departure from professional standards. In reaching a decision on sanction, it considered that, whilst a reprimand or warning would not be appropriate, neither would removing Mr Okano's name from the Register be proportionate, or necessary either in the public interest or to protect animals.
"Mr Okano is a young veterinary surgeon at the start of his career, who from the outset admitted his actions," said Mrs Cottrell noting that the testimonials from veterinary surgeons, veterinary nurses and clients, and his record of Continuing Professional Development demonstrated his commitment to high standards within the profession. "In reaching this decision, we have paid particular regard to the fact the false certification was neither persistent nor concealed, nor was he a senior veterinary surgeon."
The Committee directed Mr Okano's name be suspended from the Register for eight months.
Merial Animal Health has been found in breach of the NOAH Code of Practice for literature promoting the wormer Ivomec Super.
In the literature, Merial stated that Closantel injection (Janssen Animal Health) was effective against flukes aged 9 weeks or older, when in fact, at the time the undated brochure was distributed, Closantel was effective against flukes aged 7 weeks or older.
Merial did not dispute the facts alleged: the company had relied on an out-of-date detailer. The NOAH Code of Practice Committee emphasised the need for members to ensure, when giving comparative data in promotions, that up-to-date data is used. The SPC of any authorised product can be viewed on the VMD's website.
The Committee did commend Merial Animal Health for taking corrective action within two days of notification by the Complainant.
NOAH encourages those interested in finding out more to read the full details of the Committee's rulings on the NOAH website at www.noah.co.uk/code.
Intervet/Schering-Plough Animal Health has launched Posatex (1% Orbifloxacin, 0.1% Mometasone Furoate Monohydrate and 0.1% Posaconazole, Otic Suspension), a new once-a-day treatment for otitis externa in dogs.
Posatex combines an antibacterial, an anti-inflammatory and an antifungal medication in one, seven-day treatment which the company describes as the 'next generation' treatment for severe otitis externa in dogs, designed to make compliance easier and bring fast relief to dogs suffering from this painful condition.
Allan Weingarten, Director, Pharmaceutical Research, and Posatex R&D Project Leader, said: "As every dog owner knows, this is a 'nightmare' disease. As experts in otic products, we feel a special responsibility to keep improving medications and continuing to make the course of treatment more effective, quicker and easier for both dogs and their caregivers. The novel triazole antifungal posaconazole, new to animal health, is the latest example of innovation in this product area."
Posatex Otic Suspension, available in 7.5, 15 and 30g plastic bottles, is indicated for the treatment of otitis externa associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (coagulase positive staphylococci, Pseudomonas aeruginosa and Enterococcus faecalis).
According to the company, posaconazole, the newest element in the three-in-one combination, has been shown to be particularly effective against Malassezia pachydermatis and more potent than other veterinary antifungals. Mometasone furoate monohydrate is a potent and safe anti-inflammatory and Orbifloxacin is a broad-spectrum antibiotic with proven efficacy against bacteria.
Animalcare has launched Vetaclean, a new range of disinfectants which the company says has a notably high kill activity against canine parvovirus and common feline viruses such as FIV, FeLV and FCV.
The range comprises Vetaclean Parvo Advance, a surface disinfectant-cleaner, Vetaclean enzymatic instrument detergent-cleaner, and an instrument disinfectant.
Animalcare Product Manager, Tony Liepman, said: "Veterinary nurses tell us that canine parvovirus is the most challenging and resistant pathogen they work with, and so we set this as our benchmark for the Vetaclean disinfectant products. Tested under EN protocols and having 99.99% + kill activity against parvovirus, our new disinfectants demonstrate high efficacy against a broad range of bacteria, including MRSA/MRSP, fungi, viruses, mycobacteria and spores.
"Infection control is in the spotlight at the moment, highlighted by initiatives from within and outside our industry. Firstly, the new Practice Standards Scheme - launched at the same time as our range - places great emphasis on having a rigorous biosecurity policy. This includes requirements for personal hygiene as well as cleanliness of premises and equipment. High-level decontamination of instruments and equipment is ensured through the Vetaclean two-stage process, which works with even soiled instruments or equipment, and in under 20 minutes. The products have also been designed to be suitable for use on the most specialised equipment seen in today’s practices, including flexible or rigid endoscopes, ultrasonic baths, aspirators, arthroscopes and re-processing machines.
"Importantly, the active ingredients in the Vetaclean range meet the criteria of the new EU Biocides Regulations, policed by the Health and Safety Executive in the UK, which came into effect on 1st September 2015. All products with biocidal activity now need to undergo a complex registration process, ensuring the products are not harmful to people, the environment or animals. The rigorous process may see many disinfectant manufacturers pull out of the market, resulting in less choice. Further, the Vetaclean range does not contain Poly (hexamethylene biguanide) hydrochloride (PHMB). The European Chemicals Agency (ECHA) is currently proposing that PHMB is listed as a category 2 carcinogen."
The Vetaclean Parvo Advance range includes a 1 litre lavender product in a self-dosing bottle, 5 litre apple and lemon-fragranced liquid concentrates and unfragranced large surface wipes. There are two different dilution rates: a general purpose dilution rate for most pathogens at 1:100 (10ml per litre), and a parvocidal dilution rate at 1:50 (20ml per litre). Animalcare says the alkaline-based formula ensures that the products are compatible with a wide range of materials and are non-staining. Both the enzymatic instrument cleaner and instrument disinfectant are available in 2 litre concentrates (incorporating a calibrated dosing reservoir).
The Vetaclean range is available now in wholesalers. The company has also produced a brochure Hygiene in practice, a guide to veterinary infection control from Animalcare, designed to help familiarise veterinary professionals with the principles and uses of the product range. There is also a special launch offer of Buy-4-Get-One-Free available from Animalcare representatives.
For further information, contact Animalcare on 01904 487687, or speak to your regional Animalcare representative: www.animalcare.co.uk/contact-us.
Vouchers for twelve months' free access to Improve's Online Bitesize CPD series will be offered to veterinary surgeons, nurses and practice managers by their Protexin Territory Manager, based on their use of products in the Protexin range.
Online Bitesize CPD offers veterinary professionals the opportunity to meet their annual CPD requirements in short bursts of learning at a time and place to suit them. Its online modules of 20, 40 and 60 minutes cover a range of clinical topics, including cardiology, ophthalmology, small animal medicine, feline medicine and exotics.
Improve says the modules have been designed to be visually engaging, highly interactive and informative to ensure that the experience is rewarding.
James Kyffin, Veterinary Director at Protexin, said: "We are thrilled to be continuing our relationship with Improve International by offering practices access to its Online Bitesize CPD. We are passionate about education and Bitesize offers a convenient, exciting way for the profession to gain access to high quality CPD."
John Douglass at Improve International added: “We hope that veterinary professionals who have not yet experienced our training will take up the opportunity created by this association with Protexin Veterinary and learn new skills with our Online Bitesize CPD service for twelve months at no cost.
"The interactive modules we have created are led by recognised experts and will help them to refresh their knowledge, learn new skills and achieve their annual CPD points quota online at any time.”
MSD says the new license claim means the vaccine combines the broadest calf scour protection available with unique user convenience.
MSD Animal Health livestock veterinary adviser Dr Kat Baxter-Smith said: “When correctly administered as a single 2ml intramuscular dose to pregnant cattle 12-3 weeks prior to calving, Bovilis Rotavec Corona boosts antibodies in colostrum for rotavirus, coronavirus and now both E.coli F5 (K99) and F41.
"Calves gain protection against these infectious scour pathogens by drinking the fortified colostrum from their vaccinated mothers.
“Bovilis Rotavec Corona also contains the most prevalent rotavirus strain in Europe2, which minimises the chances of a calf scour protection breakdown due to differences between vaccine antigens and the ubiquitous antigens on farm3.”
Kat added: "Vet, RAMA and farmer feedback suggests the wide vaccination window (12-3 weeks pre-calving) and the fact that an opened bottle of vaccine lasts for up to 28 days are particularly useful practical benefits in a mix of both dairy and beef suckler systems.”
Bovilis Rotavec Corona is available in 5, 20 and 50-dose packs from both veterinary professionals and the agricultural merchant trade.
References
Ms Bucur MRCVS faced three charges against her.
The first charge was that in April 2024, she wrote a prescription for 60 tablets of tramadol 50mg, indicating that it was for the treatment of an animal, when it was intended for the treatment of a human.
The second charge was that she allowed the prescription to be presented at a pharmacy and/or failed to stop that.
The third charge was that her conduct, in relation to the first two charges was dishonest, and misleading, and took place in circumstances where she was not professionally qualified to write a prescription for human use.
At the outset of the hearing, Ms Bucur admitted all the charges and the Committee accepted her admissions.
In relation to charge three, the Committee found that Ms Bucur had been aware that she should not have written the prescription, that she should not have indicated that it was for an animal, that she should not have deleted the prescription for the clinical record on the practice management system, and she should not have allowed or failed to prevent the prescription from being presented for dispensing.
The Committee therefore found all charges proved.
In terms of aggravating factors, the Committee considered that Ms Bucur’s conduct had given rise to a risk of injury because she was not professionally qualified or sufficiently informed to issue a prescription for tramadol, that she had acted recklessly with regard to the potential effects of a controlled, potentially addictive drug and that her conduct had been premeditated.
It also accepted the submission that there was an abuse of Ms Bucur’s professional position as a registered veterinary surgeon, because this had allowed her to issue a prescription.
The Committee also found that Ms Bucur’s conduct was aggravated by her having involved other persons in her misconduct, namely her partner, in an attempt to have the prescription dispensed.
The Committee noted that the charges involved findings of dishonesty, which is regarded at the higher end in terms of the spectrum of gravity of misconduct.
In mitigation, the Committee took into account that the facts proved related to a single incident of the issuing and attempted use of a prescription.
The Committee was of the view that the Ms Bucur’s conduct had failed to promote protection of public health and had breached the legislation around access to controlled drugs.
Even though this was a single incident, the Committee considered that members of the public, if aware of the facts, would be alarmed and concerned at Ms Bucur’s actions.
As a result, the profession could be brought into disrepute and public confidence in the profession undermined.
The Committee therefore found that Ms Bucur’s conduct amounted to serious professional misconduct in a professional respect.
The Committee then considered whether there were any relevant additional personal aggravating or mitigating factors.
The Committee did not find any further aggravating factors; in mitigation it noted that Ms Bucur had no previous complaints of adverse matters in her career.
The Committee accepted that Ms Bucur had made early, open and frank admissions to her conduct.
She had also offered a fulsome and genuine apology and remorse in her witness statement and in the hearing.
The Committee also accepted that she had since worked without further incident and concluded from her witness statement and evidence that she had developed full insight into her misconduct.
She was able to provide a notable number of references and testimonials which were uniform in speaking to her positive qualities as a veterinary surgeon.
The Committee was able to conclude that this has been a very serious but single lapse of judgement, and that there was a relevant context in that Ms Bucur had clearly acted out of concerns to help her father, however misguided.
There were no suggestions of harm, or risk of harm, to animals.
However, the Committee could not ignore that Ms Bucur’s misconduct had occurred in relation to a controlled drug and had contravened important protections designed to protect the public.
Neil Slater, chairing the Committee and speaking on its behalf, said: “The Committee balanced the effect that a suspension would have on Dr Bucur, by depriving her of the ability to practise for a period, with the public interest.
"However, it decided that, in the circumstances, the interests of protecting the public, including the wider public interest, outweighed Dr Bucur’s interests.
“The Committee decided that, in all the circumstances, a suspension was the appropriate and proportionate sanction.
“The Committee considered for how long the suspension should be imposed.
"It considered that the suspension was not required to allow for Dr Bucur to gain any further insight.
"It would purely be required to mark the Committee’s disapproval of Dr Bucur’s misconduct, as a signal to the public and to the profession.
"The Committee concluded that the least period required in all the circumstances is two months.
“The Committee therefore directed to the Registrar that Dr Bucur’s registration be suspended for a period of two months.”
https://www.rcvs.org.uk/concerns/disciplinary-hearings
The intranasal vaccine can be administered to calves from one week old. It reduces the clinical signs of respiratory disease and viral shedding from infection with Bovine Respiratory Syncytial Virus (BRSV) and Parainfluenza-3 Virus (Pi3V).
MSD says that no other UK-licensed BRD vaccine can be administered earlier in life, and claims the vaccine delivers the fastest on-farm protection, with an onset of immunity after administration of 5 days for BRSV and 7 days for Pi3V. Duration of immunity is 12 weeks for both viruses.
MSD Animal Health livestock veterinary adviser Dr Kat Baxter-Smith said: "Having this early life calf pneumonia vaccine available in single dose vials will give farmers more practical leeway to be able to vaccinate vulnerable young calves from as young as a week of age, rather than delaying administration until a batch of calves are available. We know that early-age protection of young calves through intranasal vaccination can help prevent pneumonia and positively impact a beef or dairy calf’s productive future".
The new single dose vials are supplied in packs of five, complementing the five dose vials already available.
For further information, contact your MSD account manager.
Zoetis has launched Suvaxyn Parvo/E, a combined vaccine which it says provides the earliest protection of gilts against parvovirus and erysipelas.
Parvovirus and erysipelas infections occur primarily in gilts and sows, negatively impacting their reproductive success and the health of their litters - inevitably reducing profitability.
Nigel Lodge, National Veterinary Manager for Zoetis, said: "The combined vaccine will help ensure the health of gilts and sows is not affected by these two infections which are widespread in the pig herd.
"Suvaxyn® Parvo/E gives the earliest protection so that the ability to vaccinate gilts at five months of age will help ensure a good start to their reproductive life. Up to half of all pigs may be carriers of erysipelas and importantly the vaccine has licensed efficacy against both Erysipelothrix serotypes 1 and 2.
"This brings another vaccine to our portfolio, making it one of the largest in the pig sector and confirming the ongoing commitment of Zoetis to the health and welfare of pigs."
Suvaxyn® Parvo/E is an inactivated combination vaccine approved for immunising gilts and sows to prevent reproductive disorders caused by porcine parvovirus and reduce clinical signs caused by Erysipelothrix rhusiopathiae.
Primary vaccination is recommended from five months of age, with two injections given three to four weeks apart, ensuring the second dose occurs at least four weeks before mating. Revaccination should take place three to four weeks before each subsequent mating.
The vaccine comes in 10-dose and 2 X 25-dose packs. For more information, contact your Zoetis Pig Key Account Manager.
60 veterinary surgeons, nurses and other team members from White Cross practices in Tividale, Guiseley, West Derby and Alvaston have formed 20 teams of three people, logging a total of 30,000 miles since the initiative was launched in February, or an average of 11,000 steps per team member per day.
James Harris MRCVS from White Cross Vets said: "We spend a lot of the day on our feet but really had no idea about the distance that we clock up. There are about 2,000 steps in a mile so we are walking more than five miles every day! We are always encouraging our clients to make sure their pets have a healthy lifestyle, so it’s great to practise what we preach.
"As well as the steps we take throughout the day many of us are also committed to sports and exercise regimes outside work and that has helped us to reach the top of the leaderboard for a few weeks. You might even find some of us marching on the spot to boost our step-counts and heart rates, so the Fitbit challenge is definitely keeping us active."
General manager Jo Jobling said: "We understand the vital importance of both physical and mental wellbeing, and our Fitbit challenge is a great way for our teams from across our 19 practices to work together to achieve a worthwhile healthy goal, as well as creating some healthy competition with colleagues in other practices. We also have an individual steppers league table which was recently topped by one of our veterinary nurses, Katie Rose from our Tividale practice. It might have helped that she completed a half marathon over that weekend though!"
Barclaycard has launched Paywag, a new NFC payment system for dogs.
Installed in a specially designed dog collar, the new system allows dogs to make payments up to £5.00 in value in selected pet stores and veterinary practices.
Laura Padron Vega was struck off in December 2018 after dishonestly backdating two statutory Certificates of Competence submitted to the Food Standards Agency under the Welfare of Animals at the Time of Killing Regulations 2015.
She was also found to have failed in her duties as an OV because she was unprepared for, and unaware of, the new regulations and did not take adequate steps to ensure that the two people for whom she had given veterinary certification were licensed to perform slaughter in accordance with the regulations.
At the outset of the restoration hearing, Ms Padron Vega admitted her guilt and made representations that she appreciated the seriousness of her actions and that there was no chance of her repeating them. She also produced a number of testimonials, including some from former veterinary colleagues, in addition to evidence that she had endeavoured to keep up-to-date with her continuing professional development while off the Register although this had been difficult due to her financial circumstances.
In considering her application for restoration, the Committee found that Ms Padron Vega had accepted the reasons for her removal from the Register and the seriousness of the findings. It found that she was unlikely to repeat the behaviour and that her conduct had been entirely acceptable since she was removed from the Register. It also considered her financial and personal circumstances, noting the difficulty she had in securing well-paid, full-time employment since her removal from the Register, and the impact that this had on her being able to keep up-to-date with her continuing professional development.
However, the Committee expressed concerns over her efforts to keep up-to-date with the knowledge and skills she would need to return to practice and said she demonstrated “no real appreciation of what she needed to put in place to demonstrate that she can return to work safely”.
In particular it found that the CPD she had undertaken was unstructured and insufficient and that therefore she had not done enough at the present time to demonstrate that she was fit to be restored to the Register, especially as she signalled that, if restored, she hoped to work in small animal practice, an area that she had not worked in for some time.
Cerys Jones, chairing the Committee and speaking on its behalf, said: “While the Committee did not consider that the applicant was in a position to return to practice at this point, it did consider that if the applicant applies herself to a properly structured and focused Return to Practice Plan and is able to produce evidence of how she has fulfilled the requirements of that plan, then her application could prove successful within a short time.
"The outcome of the plan for a return to practice will need to ensure the continued protection of the welfare of animals as well as the interests of clients whose animals she might be called upon to treat and, most importantly, the public interest which is founded on a belief that the veterinary certification processes are beyond question or doubt."
In order to allow Ms Padron Vega sufficient time to develop this plan, the Committee adjourned the restoration hearing for seven months (until July 2021).
Ms Jones added: “This adjournment will afford [Ms Padron Vega] an early opportunity to reflect on the concerns of the Committee… and to return with a properly supported programme for the future which will show her understanding of the problems that are likely to face her on her return to practice and her proposals to meet those inevitable difficulties.”
The RCVS Disciplinary Committee has directed that a veterinary surgeon from Berkshire be removed from the Register, following his administration of a prohibited substance to a racehorse and his subsequent attempts to conceal his actions.
At a six-day hearing that concluded yesterday, James Main, a partner in the O'Gorman, Slater, Main & Partners veterinary practice in Newbury, and former lead veterinary surgeon to racehorse trainer Nicky Henderson, faced four charges of serious professional misconduct concerning his treatment of Moonlit Path, a six-year-old mare owned by The Queen.
Three of the charges related to Mr Main breaching British Horseracing Authority (BHA) rules by injecting Moonlit Path with tranexamic acid (TA) on the day she was due to race; the fourth charge related to his dishonest concealment of this treatment in his practice clinical records. Nicky Henderson had himself faced a BHA Inquiry into this case in 2009 and subsequently been sanctioned.
The Committee heard that on 18 February 2009, Mr Henderson's yard requested a veterinary surgeon attend Moonlit Path to administer an injection of Dycenene the following morning. The injection was requested as the mare was prone to exercise-induced pulmonary haemorrhage. Mr Main attended on the morning of 19 February and injected the horse with intravenous tranexamic acid. Moonlit Path raced at Huntingdon later that day, along with the eventual winner, and favourite, Ravello Bay - another horse trained by Mr Henderson. Moonlit Path finished sixth and a urine sample taken from her after the race tested positive for TA.
Of the four charges, Mr Main admitted injecting Moonlit Path with TA on the day she was due to race when he knew this breached the BHA's rule prohibiting any substance other than the horse's usual feed and water being given on race day. However, Mr Main denied knowing that, if tested, a horse would test positive for TA (thereby imposing a strict liability on the trainer); he denied administering a prohibited substance to a horse with the intention to affect that horse's racing performance; and, he denied dishonestly concealing the TA injection by omitting it from his clinical records and referring to it as a 'pre-race check'.
The Committee heard and carefully considered evidence from Mr Henderson and his employees, from BHA investigating officers and its Director of Equine Science and Welfare, from an expert equine physiologist and from Mr Main himself. In its findings, the Committee stated it was "unimpressed by Mr Henderson's evidence and surprised by his apparent lack of knowledge of the rules of racing".
Whilst the Committee accepted Mr Main believed at the time that Moonlit Path would not test positive for TA, it considered he failed to fully inform himself of the medicinal product he was using; especially so as TA does not possess a Marketing Authorisation as a veterinary medicinal product. In so doing, he did not meet his professional obligation to provide Mr Henderson with the information and advice he needed.
The Committee concluded that TA was a prohibited substance and, whilst accepting that Mr Main's concern had solely been for Moonlit Path's welfare, he had actually breached BHA rules by affecting her performance through administering such a substance.
Finally, the Committee found that Mr Main had deliberately concealed the TA injection to Moonlit Path by describing it in his notes as a 'pre-race check' - a protocol developed over several years between the practice and Mr Henderson. Such inaccurate clinical records were in breach of the RCVS Guide to Professional Conduct and led the Committee to conclude he had acted dishonestly. The Committee also found Mr Main "did not act with candour" by claiming to have administered the TA injection the day before the race. On questioning by the Legal Assessor, however, he admitted that he had known that Moonlit Path was racing the same day that he administered the injection.
Professor Sheila Crispin, chairing the Committee, said: "[We] regard it as wholly unacceptable practice that a veterinary surgeon should be party to serious breaches of rules of another regulatory body in the field of animal welfare ... and which go to the very integrity of racing.
"Whilst the findings relate to a single incident, [we] are satisfied that Mr Main's actions amounted to pre-meditated misconduct ... It is highly relevant that Mr Main held positions of responsibility within the racing industry where he was required to uphold the rules and standards of the profession," she added.
Noting Mr Main's "long and hitherto unblemished career as a highly respected equine veterinary surgeon", the Committee accepted Mr Main's evidence that the reason for the administration of tranexamic acid was solely his concern about the welfare of the horse. Nevertheless, it found his evidence was "evasive, lacking in candour and on some aspects of the case his evidence was untrue".
Professor Crispin concluded: "...proven dishonesty has been held to come at the top end of the spectrum of gravity of disgraceful conduct in a professional respect ... Having considered carefully all the mitigation put forward on Mr Main's behalf, [we] have concluded that Mr Main's behaviour was wholly unacceptable and so serious that removal of his name from the Register is required."
The allied professionals that the BVA says should be led by veterinary surgeons include: Registered Veterinary Nurses (RVNs), Official Auxiliaries/ Meat Hygiene Inspectors, embryo transfer technicians, equine dental technicians, foot trimmers, farriers, hydrotherapists, animal behaviourists and veterinary physiotherapists.
To clarify where the responsibility for a patient sits and how it is shared between veterinary surgeons and allied professionals, the new policy statement also calls for:
The regulation of allied professionals to include mandatory veterinary diagnosis and oversight and appropriate access to veterinary records as pre-requisites before treatment;
Clarity on the delegation of duties for RVNs under Schedule 3 of the Veterinary Surgeons Act and protection of the ‘veterinary nurse’ title in legislation;
Consultation with the veterinary profession on any regulatory changes that may arise as a result of technological or other innovation.
British Veterinary Association President Simon Doherty (pictured right) said: "Against an evolving landscape, it’s essential that the veterinary profession keeps pace with change and addresses the challenges and opportunities it presents.
"Vets across sectors have always worked closely with allied professionals. The hub and spoke model acknowledges and clarifies this working relationship with clear lines of accountability and responsibility for the animals under our care. It also emphasises that vets’ right to diagnose, prescribe, and undertake surgical procedures and medical treatments must not be undermined.
"An effective and efficient vet-led team can help deliver better animal health and welfare, improved client care, and more effective use of skills within the veterinary professions. Given the ongoing workforce shortages, a strengthened veterinary workforce also has the potential to ease recruitment and retention concerns for both vets and RVNs and offer improved wellbeing.
"BVA will continue working with professional bodies and organisations to formalise the hub and spoke model, promote the value of regulation, and drive up professional standards."
Sarah, who is one of twelve recognised Specialists in feline medicine working in the UK, will advise and explore the tell-tale signs of feline diabetes mellitus and how the condition is best managed.
Royal Canin says diabetes mellitus is estimated to affect around 1 in 200 cats and is the second most common endocrinopathy after hyperthyroidism. Risk factors can include gender and neuter status, lifestyle and medication history and most relevant today, obesity.
Sarah said: "The prevalence of feline diabetes mellitus is thought to be on the increase and diagnosis can be made more challenging by the stress hyperglycaemia phenomenon that cats are vulnerable to.
"By exploring and dissecting successful strategies and ways in which diabetic remission can be achieved, this webinar will hopefully assist veterinary professionals how to diagnose and manage effectively with great end results for both owner and cat."
To register for the webinar, visit: https://vetportal.royalcanin.co.uk/cpd/webinar/
Last year Petplan received over 31,000 nominations across the five award categories: Practice of the Year, Vet of the Year, Vet Nurse of the Year, Practice Manager of the Year and Practice Support Staff of the Year.
The awards are judged by an independent panel which narrows the field to three finalists in each category, who are then invited to attend the awards ceremony.
The judges are looking for examples of exceptional levels of animal care, building and sustaining great relationships with colleagues and pet owners, and those who have gone above and beyond the call of duty.
James Barnes, Head of Sales & Partnerships at Petplan, said: “The Petplan Veterinary Awards provide the perfect opportunity to say thank you for the exceptional work carried out by members of the veterinary profession, whatever their field and wherever they’re based. The Petplan Vet Awards provide a great opportunity for both clients and colleagues to recognise the dedication and talent of veterinary professionals, teams and practices, right across the UK and say a particular thank you to those who have kept up the exceptional level of care even in the midst of a global crisis."
To nominate a colleague or your practice, visit www.petplan.co.uk before nominations close on 10th January 2022.
Sporimune is the first ciclosporin oral solution to be licensed for use in both cats and dogs.
In cats with allergic dermatitis, ciclosporin has proved to be an effective alternative to prednisolone1 Dechra says it has a long-term safety record for chronic treatment of canine atopic dermatitis and remains one of the most important tools within a multi-modal strategy.
Sporimune is available with two dosing syringes per bottle – one for cats and one for dogs – that are graduated in body weight and ml.
There are three bottle sizes to allow for flexibility in dispensing and broached bottles last six months.
Dechra Brand Manager Claire Morgan said: "We are delighted to be able to introduce this popular and effective treatment for cats.
"Allergic skin disease can be challenging to diagnose and manage effectively for both owners and vets, with around 20 per cent of all small animal consultations involving skin conditions.
"Sporimune is a key component of a multi-modal approach involving guidance on allergen and flare factor avoidance and improving skin and coat hygiene to minimise clinical signs and the effects on quality of life for both animal and owner."
Reference
The company says more and more CT scanners are being used in general practice, but many teams have been telling them they're not sure if they're using their scanner optimally, or that only some of the team are confident in using it.
The online training aims help teams get the best diagnostic use of CT
The first of the sessions, on 15th June, will cover the indications and benefits of CT in small animal practice.
The second on 22nd June will look at how and when to perform CT reconstructions.
Manuel Pinilla, VetCT Supporting Radiologist and Director of Quality Assurance (pictured right), will be delivering the talks.
Manuel said: “We are seeing a rapid increase in the use of CT in first opinion practice.
"We know CT can provide vital diagnostic information in addition to the more traditional modalities of x-ray and ultrasound.
"However, it can be challenging to optimise the diagnostic capability.
"We’re keen to support veterinary teams to help them get the most out of their machine and do the best for their patients and the owners.”
To register for the training, visit: https://welcome.vet-ct.com/ctcpdwebinars
Merial Animal Health has announced the launch of its new feline vaccine Purevax Rabies in the UK and Ireland.
Merial says the product offers a simple but elegant solution to rabies vaccination, without the need for adjuvant. According to the company, the non-replicative vector is processed by the cat's immune system in the same way as a live virus, triggering both a powerful cell mediated and humoral response without the need for adjuvant. However, because the vector cannot replicate effectively in mammalian cells, there is no risk of any reversion to virulence.
Merial's Veterinary Technical Manager Kevin Whelan, said: "This is a perfect complement to our existing range of advanced technology vaccines, which already offer the benefits of highly effective protection, including updated FCV strains, without the need for adjuvant. It also represents Merial's continued commitment to the development of innovative products for the animal health market".
The vaccine is licensed for use in cats from 12 weeks of age, and administration of a single injection has been shown to provide protection against disease.
Contact your local Merial Representative or the Merial Technical Support line on 0870 6000 123 for further information.
The company, which was founded by scientists from the human field, managed to raise £8 million of Series A funding by February this year. It is now seeking further investment for an extension to that Series A funding by the autumn.
The company's Chief Scientific Officer is Professor Allan Bradley, Emeritus Director of the Wellcome Trust Sanger Institute and a Fellow of the Royal Society (pictured right). He spearheaded the development of mouse transgenics and their translational use, which provided the basis for developing canine monoclonal antibody therapies.
Allan said: "We are growing a world-class scientific team that will enable PetMedix to become a global leader in the development of novel monoclonal antibody therapies for the expanding animal health market. In the short lifetime of the company we have attracted huge talent in both our scientists and executives, and moved into the heart of the Cambridge biotech sphere with its excellent facilities and networking opportunities. The recent appointment of Dr. Fabian Kausche to the board marks our intent to become a global leader in animal health."
CEO, Dr. Tom Weaver added: "We have the people and the technology in place, and are champing at the bit to progress these therapies to reach the pets that could benefit. We know this technology has transformed the treatment and survival of human patients with a variety of conditions and we want to create the same paradigm shift in veterinary treatment options to improve welfare, quality of life and longevity for our dogs and cats."
PetMedix says it is interested in hearing from potential investment partners, and mergers and acquisitions. Contact Jolyon Martin via email: jolyon.martin@PetMedix.co.uk or telephone: +44 (0) 1223 734140,
The Health Products Regulatory Authority (HPRA) has also granted a marketing authorisation in exceptional circumstances (Article 25, 26 EU Reg 2019/6) for Bultavo 3 in Ireland.
The company says that so far, more than 40 million doses of Bultavo 3 have been distributed in Europe to help limit the spread of BTV-3.
Boehringer points to a recent field study published by the German reference laboratory Friedrich-Loeffler-Institut (FLI), which showed that vaccination of sheep and cattle with Bultavo 3 induces immunity against the virus1.
According to the study, animals vaccinated with Bultavo 3 consistently showed evidence of a protective antibody response to BTV-3, although animals vaccinated with other BTV-3 vaccines did not1.
Boehringer says it is now compiling the data needed to obtain a full marketing authorisation in accordance with Article 8 of EU Regulation 2019/6.
A new book written by a man who is both married to and brother of a veterinary surgeon (not the same one, I hasten to add), offers a husband's take on a vet's life.
Author Steve Ankers is married to Margaret Ankers MRCVS (Acorn Veterinary Surgery) and brother of John Prescott MRCVS (now retired, but remains a consultant to Robson & Prescott).
His book, called It's a Dog's Life for the Other Half, is brimfull of funny anecdotes, including: holding hands with a famous actress inside a cow's rectum; a dog who ate a Cliff Richard cassette; a cat who ate a Chihuahua but spat out the tail and a vulture who travelled hundreds of miles on a car roof-rack.
Terry Jones (you know, the Python) described the book as "Hilarious and eminently readable".
It's a Dog's Life for the Other Half may be the literary equivalent of a busman's holiday for the members of this site, but I'm half way through and it's one of those rare books that's guaranteed to bring a smile to your face at least once a page.
It's a Dog's Life for the Other Half is available now from all good bookshops, including Amazon RRP £12.99. It is also available as an e-book.
Kaminox contains potassium gluconate and B-vitamins to help dogs affected by hypokalaemia.
Originally released as an oral liquid supplement, Vetplus says this new powdered formulation offers a more concentrated level of potassium for larger pets or those that require a higher dose.
Kaminox sachets are sold in packs of 30, with a scoop provided for easy administration.
Meanwhile, the liquid supplement is available in 60ml and 120ml bottles.
www.vetplus.co.uk/products
The company's new van has a range of 146 miles before it needs recharging, and it can be recharged to 80% within 40 minutes.
That puts 60% of MWI's customers within range of its distribution centre in Stoke-on-Trent, including those in Manchester and Birmingham.
As part of its drive to establish more sustainable operations, MWI has also launched a pilot with one of its corporate customers in which they reduce the number of deliveries made per week – adopting a two or three-day a week delivery system.
The company says that since January, that has resulted in 700,000 fewer vehicle miles.
Divided into four modules, the course explores vaccines and the immune system; current and emerging strains of Leptospirosis; a practical insight into infectious disease and vaccination and the importance of getting early socialisation right.
Professor Sarah Gilbert from the Jenner Institute in Oxford presents the first CPD module. She is followed by Dr Paul Burr from Biobest Laboratories, Alan Radford from the University of Liverpool and Jon Bowen of the RVC.
John Toole, Zoetis Product Manager said: "We were extremely privileged to be able to work with such an eminent group of key opinion leaders for this CPD course. We hope participants find the interview video style of this course dynamic and insightful. Users can also find an additional module on our dog vaccine Versican Plus and how it helps meet today’s infectious disease challenges as discussed by our industry experts."
To take part in this new CPD, vets simply need to register at www.vetsupportplus.co.uk where they will be able to access all the free Zoetis learning content and receive a certificate once the CPD course is completed.